RL-007

Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia

An adaptive, randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of RL-007 in the treatment of cognitive impairment associated with schizophrenia (CIAS)